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ABSTRACT
Reports have shown a worse outcome for donor-recipient pairs mismatched for ABO blood groups in bone
marrow transplantation (BMT). These studies, however, included small and heterogenous study populations,
and not all considered bidirectional ABO incompatibility separately. Because the issue remains controversial,
we analyzed the effect of ABO mismatch on the overall survival, transplant-related mortality, and occurrence
of acute and chronic graft-versus-host disease (GVHD) in a large homogenous group of patients undergoing
allogeneic BMT. A total of 3103 patients with early-stage leukemia who underwent transplantation between
1990 and 1998 with bone marrow from an HLA-identical sibling and who were reported to the Center for
International Blood and Marrow Transplant Research were studied. The median follow-up was 54 months. A
total of 2108 (67.9%) donor-recipient pairs were ABO identical, 451 (14.5%) had a minor mismatch, 430
(13.9%) had a major mismatch, and 114 (3.7%) had a bidirectional ABO mismatch. The groups did not differ
significantly in patient or donor characteristics except for more female-to-male sex mismatch in the bidirec-
tional ABO mismatch group (P .017). In multivariate models of overall survival, transplant-related mortality,
and grade II to IV acute GVHD, there were no significant differences among the 4 groups. Bidirectional ABO
mismatch was associated with a significantly higher risk of grade III or IV acute GVHD (hazard ratio, 1.869;
95% confidence interval, 1.192-2.93; P  .006). Patients with major ABO mismatch received red blood cell
transfusions (P  .001) for a longer timer after transplantation and had a slightly slower neutrophil recovery
(P < .001). There was no evidence of a substantial effect of ABO blood group incompatibility on the outcome
of conventional BMT among patients with leukemia.
© 2005 American Society for Blood and Marrow Transplantation
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ABO Blood Group and Transplantation Outcomes
BNTRODUCTION
In contrast to solid organ transplantation, alloge-
eic bone marrow transplantation (BMT) is per-
ormed across the ABO blood group barrier in ap-
roximately one third of patients [1]. Three groups of
BO mismatch can be distinguished in BMT, as
hown in Table 1: minor, major, and bidirectional
BO incompatibility. Minor ABO incompatibility, eg,
rom an O-type donor to an A-, AB-, or B-type recip-
ent, is characterized by the ability of donor B lym-
hocytes to produce antirecipient isoagglutinins. In
ontrast, major ABO-incompatible BMT, eg, from an
-, AB-, or B-type donor to an O-type recipient, is
haracterized by the presence of preformed antidonor
soagglutinins. In bidirectional ABO incompatibility,
g, A-type donor to B-type recipient, a combination of
oth the major and minor ABO blood group barriers
ust be overcome. In the minor incompatible situa-
ion, some centers remove preformed antihost isoag-
lutinins from the graft, whereas others do not. Sev-
ral techniques are used in the major incompatible
ituation to remove either antidonor isoagglutinins
rom the recipient or red blood cells (RBCs) from the
raft.
Although ABO incompatibility increases the risk
f transplant-related hemolytic reactions [2], most
ata suggest that ABO incompatibility does not sig-
iﬁcantly alter the overall transplantation outcome
3-6], with few exceptions [7-12]. Studies from the late
970s and early 1980s on the role of the ABO blood
roup system in allogeneic BMT showed no effect
n graft-versus-host disease (GVHD) or transplant-
elated mortality (TRM) [6]. However, when these
esults were obtained, bidirectional ABO incompat-
bility was not considered separately, modern GVHD
rophylaxis was not available, and survival was poor.
ubsequently, improved subject selection and trans-
lantation techniques and better drugs led to generally
ower overall mortality. In this situation, an effect of
he ABO system on outcome may be more apparent.
ndeed, several lines of evidence suggest that minor
BO incompatibility may be associated with an in-
reased risk of GVHD and that bidirectional ABO
ncompatibility may be associated with worse survival
fter BMT [7-12]. However, some of these studies
ave evaluated relatively small and heterogenous pa-
able 1. Nomenclature for ABO Mismatching Observed and Theoretica
ABO Mismatch Donor Recipient
Minor O A, B or A
A, B AB
Major A, B or AB O
AB A, B
Bidirectional A B
B AB & M Tient populations, with conﬂicting results. Conse-
uently, the effect of ABO incompatibility deserves re-
xamination. We therefore analyzed the effect of ABO
ismatching on survival, TRM, and acute (aGVHD)
nd chronic GVHD (cGVHD) in a large and homoge-
ous group of patients receiving allogeneic BMTs.
ETHODS
ata Source
This observational study included 3103 patients
ho received allogeneic BMT from 1990 to 1998 and
ere reported to the Center for International Blood
nd Marrow Transplant Research by 232 centers. The
enter for International Blood and Marrow Trans-
lant Research is a voluntary working group of more
han 450 transplant centers worldwide that contribute
etailed data on consecutive allogeneic hematopoietic
tem cell transplantations to a statistical center at the
ealth Policy Institute of the Medical College of
isconsin in Milwaukee, WI, or the National Mar-
ow Donor Program Coordinating Center in Minne-
polis, MN. Approximately two thirds of all active
ransplantation centers worldwide report data to the
egistry. The registry database includes information
n 40% to 45% of all patients who have received an
llogeneic transplant since 1970, with annual updates.
omputerized checks for errors, reviews of submitted
ata by physicians, and on-site audits of participating
enters are used to monitor the quality of the data.
utcomes
Primary end points were overall survival, deﬁned
s death from any cause; the cumulative incidence of
eukemia relapse, deﬁned as time to recurrent disease;
he cumulative incidence of TRM, deﬁned as death
ithout relapse; and the cumulative incidence and
everity of aGVHD and cGVHD. Patients with en-
raftment were considered to be at risk for aGVHD,
nd patients surviving to day 90 were considered to
e at risk of cGVHD. Acute GVHD was grouped as
rade 0 or I versus II to IV, high-grade aGVHD was
rouped as grade III or IV versus less, and cGVHD
as assessed as limited or extensive cGVHD versus
one. Secondary end points included neutrophil en-
rse Outcomes in Allogeneic BMT Reported in Previous Studies
Known and Postulated Consequences
Recipient hemolysis
Reports of increased GVHD
Posttransplantation pure red blood cell aplasia
Reports of impaired engraftment and increased GVHD
Recipient hemolysis and red blood cell aplasia
Reports of reduced overall survivall Adve
BReports of impaired engraftment and increased GVHD
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1raftment and time to last RBC transfusion as a sur-
ogate marker for RBC engraftment. Neutrophil en-
raftment was deﬁned as an absolute neutrophil count
500/L for 3 days. Subgroup analysis in minor,
idirectional, and major ABO blood group incompat-
bilities (A into O versus B into O, O into A versus O
nto B, and A into B versus B into A) were performed
o test for differences among the more immunogenic
antigens and less immunogenic B antigens.
tatistical Analysis
Baseline characteristics among ABO blood group
atches were compared by using analysis of variance
r 2 analysis, as appropriate. For survival, aGVHD,
GVHD, TRM, relapse, time to neutrophil engraft-
ent, and time to last RBC transfusion, the Kaplan-
able 2. Baseline Characteristics of the Patients*
Variable Identical (n  2108) Major (
edian age, y (range)
Patient 33 (1-69) 34
Donor 32 (1-68) 32
iagnosis
AML 726 (34) 157
ALL 328 (16) 69
CML 1054 (50) 225
arnofsky score
>90 1815 (87) 395
<90 281 (13) 55
ex
Male 1172 (56) 281
Female 935 (44) 170
onor-recipient sex match
Male-male 665 (32) 155
Male-female 494 (23) 97
Female-male 506 (24) 126
Female-female 439 (21) 73
ace of the patient
White 1607 (76) 338
Black 142 (7) 338
Asians and others 349 (17) 78
onditioning
Bu/Cy  others 1096 (52) 223
Cy/TBI  others 754 (36) 182
Others 258 (12) 46
rowth factor use
No growth factor 1471 (70) 305
Within 7 d 306 (14) 58
After 7 d 329 (16) 88
ear of transplantation
1990-1991 665 (31) 144
1992-1993 643 (31) 136
1994-1995 386 (18) 77
>1996 423 (20) 94
onor–recipient CMV status
Negative-negative 516 (26) 115
Positive-negative 204 (10) 54
Negative-positive 307 (15) 74
Positive-positive 978 (49) 191
ata are n (%) unless otherwise noted.
LL indicates acute lymphoblastic leukemia; Bu, busulfan; Cy, cyc
Donor-recipient pairs were divided into 4 groups according to AB
Differences among the ABO-incompatible groups were analyzed by 2 o
008eier estimator or cumulative incidence curves ac-
ommodating competing risks were used as appropriate,
nd the groups were compared by using the log-rank
est. To test the effect of ABO mismatch on survival,
RM, relapse, and GVHD (grade II-IV versus 0-I and
II-IV versus 0-II), we used Cox regression, adjusting
or potential confounding variables. All reported P
alues are 2 sided, and P values .05 were assumed to
e statistically signiﬁcant.
ESULTS
atient Characteristics
The frequencies of ABO blood groups A (38%), B
14%), O (43%), and AB (5%) were similar in recip-
1) Minor (n  430) Bidirectional (n  114) P Value†
33 (1-57) 31 (1-58) .420
34 (1-71) 31 (6-62) .400
.998
150 (35) 39 (34)
63 (15) 16 (14)
217 (50) 59 (52)
.805
364 (86) 100 (88)
61 (14) 14 (12)
.006
253 (59) 77 (67)
177 (41) 37 (33)
.017
153 (36) 36 (32)
103 (24) 22 (19)
100 (23) 41 (36)
74 (17) 15 (13)
.279
313 (73) 82 (72)
31 (7) 3 (3)
84 (7) 29 (25)
.350
210 (49) 61 (53)
166 (39) 36 (32)
54 (13) 17 (15)
.131
304 (71) 76 (67)
68 (16) 25 (22)
58 (13) 13 (11)
.441
131 (30) 30 (26)
140 (33) 29 (25)
82 (19) 31 (27)
77 (18) 24 (21)
.150
103 (25) 30 (29)
51 (13) 11 (11)
63 (15) 20 (20)
192 (47) 41 (40)
phamide; TBI, total body irradiation; CMV, cytomegalovirus.
d group compatibility.n  45
(1-59)
(1-61)
(35)
(15)
(50)
(88)
(12)
(62)
(38)
(34)
(22)
(28)
(16)
(75)
(75)
(17)
(49)
(40)
(10)
(68)
(13)
(19)
(32)
(30)
(17)
(21)
(27)
(12)
(17)
(44)
lophos
O bloor analysis of variance, as appropriate.
i
c
r
(
b
t
r
b
t
p
(
1
(
a
s
p
p
p
3
a
c
t
f
i
d
r
A
t
m
2
b
a
o
g
r
S
(
s
m
r
d
p
C
C
1
p
(
O
o
a
s
s
m
s
g
a
G
t
q
s
T
d
p
i
I
g
a
a
v
I
p
1
o
h
A
t
c
g
H
m
c
d
g
5
R
T
S
A
C
R
*
†
‡
ABO Blood Group and Transplantation Outcomes
Bents and donors. A total of 2108 (67.9%) patients re-
eived an ABO-identical transplant, and 995 (32.1%)
eceived ABO-mismatched transplants, including 451
14.5%) minor, 430 (13.9%) major, and 114 (3.7%)
idirectional ABO-incompatible BMTs. Baseline pa-
ient characteristics are listed in Table 2. All patients
eceived non–T cell–depleted HLA-identical sibling
one marrow as a stem cell source. All transplanta-
ions were performed for acute leukemia in ﬁrst com-
lete remission or chronic myelogenous leukemia
CML) in ﬁrst chronic phase. The study included
072 (35%) patients with acute myelogenous leukemia
AML), 476 (15%) with acute lymphoblastic leukemia,
nd 1555 (50%) with CML. The population was re-
tricted to patients receiving standard myeloablative
retransplantation conditioning, mainly with cyclo-
hosphamide and busulfan (n  1096; 52%) or cyclo-
hosphamide and total body irradiation (n  754;
6%). GVHD prophylaxis consisted of cyclosporine
nd methotrexate. A total of 945 (30%) patients re-
eived growth factors after BMT—457 (15%) within
he ﬁrst 7 days after transplantation. The median
ollow-up time was 54 months. There were no signif-
cant differences in patient characteristics among the
ifferent ABO blood group matches except for donor-
ecipient sex mismatch. The group with bidirectional
BO incompatibility contained more female-to-male
ransplantations as compared with ABO-identical and
ajor and minor ABO-incompatible BMTs: 36% versus
4%, 23%, and 28%, respectively (P  .017). Other
aseline variables analyzed were patient and donor
ge, disease, Karnofsky performance score, race, type
f conditioning regimen, use of posttransplantation
rowth factors, year of transplantation, and donor–
ecipient cytomegalovirus status.
urvival
The overall 5-year survival probability was 62%
95% conﬁdence interval [CI], 60%-64%), with no
tatistically signiﬁcant differences among ABO-mis-
atch groups (Table 3 and Figure 1A; P  .238). Cox
egression analysis adjusting for confounding variables
id not reveal signiﬁcant differences when the trans-
lantations with major (hazard ratio [HR], 1.127; 95%
I, 0.954-1.331; P  .160), minor (HR, 1.160; 95%
I, 0.981-1.373; P  .083), and bidirectional (HR,
able 3. Survival, Relapse, and GVHD
Variable Identical (n  2108) Major (n
urvival at 5 y† 63 (61-65) 60 (55
cute GVHD at day 100‡ 29 (27-31) 32 (28
hronic GVHD at 5 y 43 (40-45) 44 (39
elapse at 5 y 17 (15-19) 17 (13
Differences in the ABO-incompatible groups were analyzed by lo
Data are percentages (95% conﬁdence interval).
Acute GVHD grade II to IV.
B & M T.016; 95% CI, 0.736-1.404; P  .922) ABO incom-
atibility were compared with ABO-identical BMTs
Table 4). Subgroup analysis of neither minor (O into A,
into B, and O into AB; P  .53) nor major (A into O
r B into O; P .78) ABO-incompatible BMT revealed
ny effect of the ABO system on survival. Survival was
igniﬁcantly inﬂuenced by patient age, disease, Karnof-
ky performance score, and female-to-male sex mis-
atch (Table 4). In univariate and multivariate analy-
es, there was no association between ABO blood
roup compatibility and TRM or relapse (Figure 1B
nd C).
raft-versus-Host Disease
The severity of aGVHD was worse after bidirec-
ional ABO-incompatible BMT even though the fre-
uency of aGVHD was not increased and overall
urvival was not affected by the more severe aGVHD.
he frequency of grade II to IV aGVHD did not
iffer among ABO blood group match groups, but
atients receiving transplants from a bidirectional ABO-
ncompatible donor had a higher risk of severe (grade
II-IV) aGVHD. The cumulative incidences of aGVHD
rade II to IV and grade III or IV are shown in Figure 2A
nd B, respectively. Cox regression analysis adjusting for
ge, sex mismatch, disease, and performance score re-
ealed a signiﬁcantly increased risk of high-grade (III-
V) GVHD in patients with bidirectional ABO incom-
atibility as compared with ABO-identical BMT (HR,
.869; 95% CI, 1.192-2.93; P  .006). This higher risk
f severe aGVHD did not, however, translate into
igher TRM risks. Subgroup analysis of bidirectional
BO-incompatible BMT showed no difference be-
ween B into A and A into B BMT. Analysis of
GVHD did not show an inﬂuence of ABO blood
roup mismatch (Figure 2C).
ematopoietic Engraftment
Major ABO-incompatible BMT, as compared with
inor ABO-incompatible and ABO-identical BMT, was
haracterized by delayed RBC recovery. In this study,
ata on the duration of RBC transfusions as a surro-
ate marker for RBC engraftment were available for
58 (18%) of 3103 patients. The median duration of
BC transfusions was 21 days (95% CI, 18-22 days)
) Minor (n  430) Bidirectional (n  114) P Value*
57 (52-62) 66 (57-75) .294
31 (27-35) 29 (22-39) .741
45 (40-50) 40 (30-50) .779
17 (14-22) 20 (14-30) .685
test. 451
-65)
-36)
-49)
-21)
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1fter ABO-identical BMT, 20 days (95% CI, 11-29
ays) after bidirectional ABO-incompatible BMT, and
1 days (95% CI, 17-25 days) after minor ABO-incom-
atible BMT. Dependency on RBC transfusions was
igniﬁcantly longer in the major ABO mismatch group
41 days; 95% CI, 21-59 days; P  .001). Additionally,
eutrophil engraftment, deﬁned as achieving an abso-
ute neutrophil count 500/L for 3 consecutive
ays, was slightly but signiﬁcantly delayed in the ma-
igure 1. A, Kaplan-Meier survival estimates of overall survival. B,
umulative incidence of transplant-related mortality. C, Cumula-
ive incidence of relapse according to ABO match. Cox regression
nalysis of the overall survival did not reveal signiﬁcant differences
mong major (HR, 1.131; 95% CI, 0.957-1.336; P .148), minor
HR, 1.157; 95% CI, 0.977-1.367; P .097), and bidirectional (HR,
.033; 95% CI, 0.748-1.426; P .844) ABO incompatibility as com-
ared with ABO-identical BMT. Identical, solid line; minor, dotted
ine; bidirectional, dashed line; major, dotted-dashed line.or ABO-incompatible group: 19 days (95% CI, 18.7-
0109.3 days) after ABO-identical BMT, 20 days (95%
I, 18.5-21.5 days) after bidirectional ABO-incom-
atible BMT, 19 days (95% CI, 18.3-19.7 days) after
inor ABO-incompatible BMT, and 21 days (95%
I, 20.4-21.6 days) after major ABO-incompatible
MT (P  .001).
ISCUSSION
The goal of this study was to determine the po-
ential effects of ABO mismatching on the outcome of
llogeneic BMT. This observational, multicenter study
ncluded a population of more than 3000 patients who
nderwent transplantation for AML, acute lympho-
lastic leukemia, or CML. All patients received stan-
ard BMT, deﬁned as BMT from HLA-identical sib-
ing donors by using myeloablative pretransplantation
onditioning and immune suppression with cyclospor-
ne and methotrexate. When ABO-identical BMT was
ompared with ABO-incompatible BMT, no differ-
nces were found in survival.
Previous studies had shown equivocal results, in-
luding 2 recent studies that showed lower survival for
atients undergoing bidirectional ABO-incompatible
MT [8,11]. The number of patients with bidirec-
ional ABO incompatibility, however, was small in
oth studies. In contrast, data from the Seattle group
hat analyzed 716 ABO-incompatible transplantations
emonstrated no differences in survival, including 30
atients with bidirectional ABO incompatibility who
nderwent HLA-identical BMT from a related donor.
enjamin and Antin [13] reported an increased risk for
nfectious deaths and multiorgan failure in patients
ith AML or myelodysplastic syndrome during the
able 4. Cox Regression Analysis of Overall Mortality*
Variable
Hazard
Ratio 95% CI
P
Value
BO blood group .238
ABO identity 1.000 — —
ABO major mismatch 1.127 0.954-1.331 .160
ABO minor mismatch 1.160 0.981-1.373 .083
ABO bidirectional
mismatch 1.016 0.736-1.404 .922
ge 1.018 1.013-1.023 <.001
isease <.001
AML 1.000 — —
ALL 1.383 1.165-1.642 <.001
CML 0.803 0.700-0.921 .002
arnofsky score >90 0.801 0.681-0.943 .008
ex match .139
Male-male 1.000 — —
Male-female 1.075 0.914-1.264 .383
Female-male 1.205 1.030-1.409 .020
Female-female 1.091 0.919-1.295 .320
LL indicates acute lymphoblastic leukemia.
Cytomegalovirus match, year of transplantation, and conditioning
regimen were also analyzed but excluded because they did not
inﬂuence the overall survival.
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Brst 100 days after minor or major ABO-incompatible
ematopoietic stem cell transplantation. This was as-
ribed to the transfusion of blood products without
rior removal of donor plasma, resulting in the trans-
er of large amounts of antirecipient isoagglutinins.
fter the transfusion policies were changed, signiﬁ-
ant ABO-related differences in survival were no
onger detectable [14]. These ﬁndings highlight the
mportance of transfusion policies and pretransplan-
ation measures to reduce anti-A/B antibodies in
BO-incompatible BMT.
igure 2. A, Cumulative incidence of acute GVHD grade II to IV.
, Cumulative incidence of acute GVHD grade III or IV. C,
umulative incidence of chronic GVHD according to ABO match.
ox regression analysis revealed an increased risk for grade III or IV
GVHD after bidirectional ABO-incompatible BMT (HR, 1.869;
5% CI, 1.19-2.93; P  .006) as compared with identical and major
nd minor ABO-incompatible BMT. Identical, solid line; minor,
otted line; bidirectional, dashed line; major, dotted-dashed line.In a single-center analysis, higher TRM and c
B & M TGVHD were reported 7 years after transplantation in
atients with major ABO incompatibility. This sug-
ested a potential effect of the ABO system on long-
erm outcome [15]. Other studies of ABO incompat-
bility in allogeneic BMT, however, did not detect an
ffect on overall survival [3,4,6,12]. It is quite possible
hat smaller studies showing discordant results on the
nﬂuence of ABO matching are subject to biases due to
eterogenous patient populations. In this study, re-
apse rate and TRM were similar in ABO-identical
nd -mismatched BMT. This is in contrast with a
eport by Mehta et al. [16], who observed a decreased
elapse rate but no differences in the incidence of
GVHD or cGVHD after ABO-mismatched trans-
lantations in 43 patients. Similar results were re-
orted recently in 19 patients receiving nonmyeloab-
ative ABO-incompatible peripheral blood stem cell
ransplants [17]. ABO incompatibility resulted in
igher TRM and a trend toward a reduced relapse but
ad no effect on GVHD. These studies, however,
ooled all subgroups of ABO-mismatched transplants
o compare with ABO-matched transplants, and this
recludes meaningful interpretation of the results. If
BO mismatching were to result in more graft-
ersus-leukemia effects, this would be expected to
ccur only in the donor-directed (minor ABO mis-
atch) and not in the host-directed (major ABO
ismatch) setting.
Both aGVHD and cGVHD mainly depend on
lloreactive T cells. However, it is not known whether
lloreactive natural anti-A/B antibodies also contrib-
te to the pathogenesis of GVHD. In support of the
atter hypothesis, 2 reports found an increased risk of
GVHD after minor ABO-incompatible BMT and a
ecreased risk after major ABO-incompatible BMT
9,18]. The explanation for this result was that donor
ymphocytes, otherwise responsible for the induction
f GVHD, absorbed anti-A/B antibodies of the recip-
ent and became susceptible to elimination by anti-
ody-mediated cell lysis. In agreement with this ob-
ervation, it was reported recently that the incidence
f aGVHD (grade I-IV) was higher in minor ABO-
ncompatible stem cell transplantation as compared
ith ABO identity [8]. This difference was limited to
ild GVHD, whereas in moderate to severe GVHD
grade II-IV), no signiﬁcant difference was found. In
his study, ABO blood group matching did not have a
ajor effect on the incidence of GVHD, with the
xception of patients with bidirectional ABO-incom-
atible BMT, who had a slightly higher incidence of
rade III or IV aGVHD. It is of note that the multi-
ariate analysis adjusted for the higher number of
emale-to-male transplantations in the bidirectional
BO-incompatible BMT group and therefore cannot
xplain the difference in aGVHD. However, the in-
reased risk of grade III or IV GVHD was not asso-
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1iated with a higher TRM and should therefore be
nterpreted cautiously.
Both dependency on RBC transfusions and neu-
rophil recovery were delayed in the group with major
BO-incompatible transplants. This might be ex-
lained either by a higher incidence of hemolysis or by
elayed RBC recovery, both of which could be medi-
ted by antidonor A/B antibodies. The mechanism
eading to delayed RBC engraftment after major
BO-incompatible BMT and the measures of preven-
ion are a matter of debate [1]. Unfortunately, this
uestion cannot be resolved by the current study.
ecause there were no prospective criteria for giving
BC transfusions, we also cannot exclude the possi-
ility that physicians were more likely to give RBC
ransfusions to recipients of ABO-incompatible trans-
lants. Assessment of hemolysis after BMT is chal-
enging because all commonly used parameters for
etection of hemolysis lack speciﬁcity after BMT.
oreover, reticulocyte counts as a measure for the
unction of erythropoiesis were not available. How-
ver, there are several reports in the literature on cases
f pure red cell aplasia after major ABO-incompatible
MT, some of which state a correlation with the level
f antidonor isoagglutinins before BMT, although the
vidity of the antibodies was not analyzed [17,19-21].
here was not prolonged duration of RBC transfu-
ions in the bidirectional ABO-incompatible group, in
hich antidonor antibodies were also prevalent.
The ﬁnding of a delay of approximately 2 days in
eutrophil engraftment after major ABO-incompatible
MT has not been reported previously. There was no
ifference in growth factor use among the ABO
roups. The most likely explanation for this ﬁnding,
herefore, is the presence or generation of antidonor
/B or neutrophil antibodies [22-26]. More speciﬁ-
ally, it is likely that high pretransplantation levels of
ntidonor isoagglutinins and/or residual host B and
lasma cells escaping the conditioning regimen may
e responsible for the observed delay. Antidonor A/B
ntibodies may bind to A/B antigens absorbed on the
urface of neutrophils or their precursors in the bone
arrow, thus leading to elimination or suppression.
ONCLUSION
In conclusion, this study corroborates the gener-
lly applied practice of allogeneic BMT across ABO
arriers, because there was no extra risk of failure of
ngraftment, TRM, or relapse. This ﬁnding indeed
s reafﬁrming and underlines that the use of ABO-
ncompatible transplants in the modern era of allo-
eneic BMT is safe and not associated with major
isadvantages. The major limitation of this study is
he lack of information on pretransplantation process-
ng of the bone marrow and posttransplantation trans-
012usion policies. Furthermore, additional studies are
eeded to address the role of ABO incompatibility in
ewer forms of stem cell transplantation, such as alter-
ative stem cell transplant sources, donor types, and
educed-intensity conditioning regimens.
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